Yablonka Uri 4
4 · BRAINSTORM CELL THERAPEUTICS INC. · Filed May 29, 2026
Research Summary
AI-generated summary of this filing
BrainStorm (BCLI) EVP Uri Yablonka Receives 150,000 RSU Award
What Happened
- Uri Yablonka, EVP & Chief Business Officer and Director of BrainStorm Cell Therapeutics (BCLI), received an award of 150,000 restricted stock units (RSUs) on February 26, 2026. The award was granted at $0.00 (no cash paid at grant). This is a compensation grant rather than a market purchase or sale.
Key Details
- Transaction date: 2026-02-26; Grant type: Award/Acquisition (RSUs); Price reported: $0.00.
- Vesting: 50% of the RSUs vested on the grant date; the remaining 50% vests on the six‑month anniversary of the grant, contingent on continued employment (per footnote).
- Shares owned after transaction: Not specified in the provided filing.
- Filing date: 2026-05-29 (Form 4 filed ~3 months after the grant). This appears later than the typical 2-business-day Form 4 reporting requirement.
- Accession: 0001104659-26-068338.
Context
- RSUs are a form of equity compensation that convert into company shares upon vesting; no shares were purchased or sold in this transaction. Such grants are common for executive compensation and retention; they do not by themselves indicate a buy or sell signal.
Insider Transaction Report
Form 4
Yablonka Uri
DirectorEVP & Chief Business Officer
Transactions
- Award
Common Stock
[F1]2026-02-26+150,000→ 218,464 total
Footnotes (1)
- [F1]Represents shares of restricted stock units ("RSUs") awarded under the Plan. The RSUs shall vest as to (i) 50% of the award on the date of grant and (ii) the remaining 50% of the award shall vest on the six-month anniversary of the date of grant, provided that the Reporting Person remains employed by the Issuer through each applicable vesting date.
Signature
/s/ Uri Yablonka|2026-05-29